Inhibition of periplocin on human hepatoma carcinoma and breast carcinoma cells in vitro
Inhibition of periplocin on human hepatoma carcinoma and breast carcinoma cells in vitro
复制标题
DOI：
--
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Ding Fei-fe
中科院分区：
文献类型：
--
作者：
Ding Fei-fe
目的探讨哌嗪对乳腺癌MDA-MB-468细胞和肝癌HepG2细胞体外增殖的影响。方法采用MTT法检测MDA-MB-468和HepG2细胞的增殖情况，采用流式细胞术观察periplocin对两种肿瘤细胞周期的影响。结果与对照组相比，periplocin对两种细胞的增殖均有明显的抑制作用，且抑制率与药物剂量、作用时间呈正相关。流式细胞术检测发现，经24h处理后，periplocin诱导MDA-MB-468和HepG2细胞的细胞周期（G0 /G1）阻滞。结论哌替星能抑制乳腺癌MDA-MB-468和肝癌HepG2细胞的增殖，使其细胞周期阻滞在G0 /G1期。
Objective To discuss the effect of periplocin on the proliferation of the breast carcinoma MDA-MB-468 cells and hepatocellular carcinoma HepG2 cells in vitro. Methods MTT method was used to examine the proliferation of MDA-MB-468 and HepG2 cells, and flow cytometry was used to observe the effect of periplocin on cell cycle of the two kinds of tumer cells. Results Compared with the control group, periplocin could obviously inhibit the proliferation of two kinds of cells, and the inhibitory rate was positively correlated with drug level and action time. By flow cytometry, it was found that after 24 h treatment, periplocin induced cell cycle(G0 /G1) arrest in MDA-MB-468 and HepG2 cells. Conclusion Periplocin could inhibit the proliferation of the breast carcinoma MDA-MB-468 and hepatocellular carcinoma HepG2 cells, and block their cell cycle in G0 /G1 phase.